Travere Therapeutics, Inc. (TVTX) key performance indicators and operating metrics (19 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net income (non-GAAP adjusted) | 4.1M | FY2026-Q1 |
| New patient start forms (PSFs) | 993.00 | FY2026-Q1 |
| U.S. net product sales (FILSPARI) | 105.2M | FY2026-Q1 |
| New PSFs | 993.00 | FY2026-Q1 |
| R&D expenses (GAAP) | 57.1M | FY2026-Q1 |
| R&D expenses (non-GAAP adjusted) | 51.5M | FY2026-Q1 |
| SG&A expenses (GAAP) | 80.3M | FY2026-Q1 |
| SG&A expenses (non-GAAP adjusted) | 69.3M | FY2026-Q1 |
| U.S. net FILSPARI sales | 105M | FY2026-Q1 |
| U.S. patients with pathway to access | 96.00 percent | FY2026-Q1 |
| Total other income, net | 200K | FY2026-Q1 |
| R&D expense (GAAP) | 57.9M | FY2025-Q4 |
| R&D expense (non-GAAP adjusted) | 54M | FY2025-Q4 |
| SG&A expense (GAAP) | 101.7M | FY2025-Q4 |
Back to TVTX overview · TVTX earnings · TVTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.